Clinical Trial Update: Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating the combination of tofacitinib with meglumine antimoniate for cutaneous leishmaniasis (American type) across Phase 2 and Phase 3 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Meglumine antimoniate (meglumine antimoniate)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Hospital Universitário Professor Edgard Santos | Conditions: Cutaneous Leishmaniasis, American | Phase 2, Phase 3 | Status: UNKNOWN